Compare Estee Lauder Companies Inc (EL) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Neurocrine Biosciences Inc — how do they compare? Estee Lauder Companies Inc trades at $93.37 (market cap $34.17B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Estee Lauder Companies Inc is far larger — about 2.4× Neurocrine Biosciences Inc's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EL | NBIX | |
|---|---|---|
Market Cap | $34.17B | $14.36B |
Volume | 3,921,497 | 1,237,180 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $185.50 |
52-Week Low | $67.23 | $123.10 |
Typical Hold Time | 122 Days | 23 Days |
Enterprise Value | $39.92B | $14.37B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $94.45, up 1.17% with a bullish technical signal from moving averages. The company shows mixed fundamentals with a high P/E ratio of 188.9 but strong gross margins of 75.5%. Recent earnings beats in Q4 2025 and Q1 2026 contrast with a net loss of $1.13B in 2025. Analyst consensus is positive with 47.8% buy ratings and a $103 price target. Recent developments include AI partnerships and leadership changes.
Outlook remains cautiously optimistic as the company navigates profitability challenges while investing in digital transformation. Key opportunities include margin recovery and AI-driven growth initiatives, balanced against competitive pressures and execution risks in the beauty sector. The stock offers potential upside to analyst targets if turnaround efforts succeed.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
